Introduction
Precise modification and reform of antibody orientation, this platform is used to enhance antibody-dependent cell killing.
For the first time in the world, Talen's technology is used to knock out fucose to improve ADCC. The method patent is authorized by China and the only patent of its kind in China. Technology is in the international leading level. The resulting cell lines are stable and can develop more than 10 clinically confirmatory targets for hematoma， solid tumors and autoimmune diseases(For example, CD20, Her2, EGFR, CCR 4, CTLA 4, PDGFR, CD38, GD2, CD19, MUC 1, etc), second generation "Me better" mAb or bispecific antibody, multiple specific antibodies.
